Bay­er's next-gen drug Nube­qa aces sur­vival test in metasta­t­ic prostate can­cer, putting it in com­pe­ti­tion with gi­ants

In the bat­tle for mar­ket dom­i­nance in prostate can­cer, Bay­er’s Nube­qa has made a late en­try in­to the field but holds high hopes for even­tu­al suc­cess. New late-stage da­ta could un­der­score a sec­ond in­di­ca­tion, which would bode well for the drug’s chances.

Adding Bay­er’s Nube­qa to an­dro­gen de­pri­va­tion ther­a­py and chemother­a­py do­c­etax­el cut the risk of death by 32.5% against ADT/do­c­etax­el alone in pa­tients with metasta­t­ic hor­mone-sen­si­tive prostate can­cer, the Ger­man drug gi­ant said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER